Table 2.
Factors associated with initiation of rivaroxaban, apixaban, or dabigatran, vs. VKA in patients with VTE.
| variables | Odds ratios | ||
|---|---|---|---|
| Rivaroxaban vs. VKA | Apixaban vs. VKA | Dabigatran vs. VKA | |
| Sex | |||
| Female | Ref | Ref | Ref |
| Male | 1.05 (0.98–1.12) | 1.04 (0.90–1.21) | 0.88 (0.58–1.33) |
| Age groups | |||
| <65 | Ref | Ref | Ref |
| 65–75 | 1.01 (0.92–1.10) | 0.99 (0.81–1.20) | 1.42 (0.83–2.39) |
| >75 | 1.00 (0.92–1.09) | 1.31 (1.08–1.58)* | 1.61 (0.96–1.36) |
| Index event | |||
| Deep venous thrombosis | Ref | Ref | Ref |
| Pulmonary embolism | 1.05 (0.98–1.12) | 1.68 (1.44–1.95)* | 1.20 (0.79–1.82) |
| Comorbidities | |||
| Previous VTE | 0.78 (0.71–0.86)* | 0.73 (0.57–0.93)* | 0.68 (0.33–1.27) |
| Previous bleeding | 1.01 (0.90–1.13) | 0.92 (0.72–1.18) | 0.82 (0.37–1.58) |
| Alloplastic surgery | 1.22 (0.97–1.54) | 1.03 (0.60–1.70) | 0.97 (0.16–3.23) |
| Chronic kidney disease | 0.42 (0.34–0.50)* | 0.47 (0.32–0.69)* | NA |
| Liver disease | 0.73 (0.57–0.95)* | 0.93 (0.54–1.55) | NA |
| Heart failure | 1.26 (1.06–1.50) | 0.80 (0.55–1.16) | 1.03 (0.30–2.74) |
| Ischemic heart disease | 0.87 (0.75–0.99)* | 1.21 (0.91–1.59) | 0.45 (0.13–1.14) |
| Vascular disease | 0.89 (0.70–1.13) | 0.72 (0.40–1.22) | 1.44 (0.34–4.05) |
| Hypertension | 0.89 (0.82–0.97)* | 0.93 (0.77–1.11) | 0.48 (0.26–0.83)* |
| Acute myocardial infarction | 0.85 (0.62–1.17) | 1.49 (0.77–2.29) | 0.76 (0.08–5.97) |
| Cancer | 0.74 (0.67–0.82)* | 0.76 (0.60–0.94)* | 0.92 (0.50–1.60) |
| Diabetes mellitus | 1.00 (0.88–1.14) | 0.95 (0.71–1.24) | 0.94 (0.39–1.97) |
| Stroke | 0.86 (0.75–0.99)* | 1.19 (0.90–1.56) | 1.30 (0.57–2.61) |
| COPD | 0.88 (0.78–0.99)* | 1.08 (0.84–1.37) | 1.80 (0.99–3.10) |
| Thrombophilia | 0.58 (0.42–0.78)* | 0.27 (0.08–0.69)* | 1.75 (0.96–3.02) |
| Year (with 1 year increments) | 2.21 (2.15–2.27)* | 4.49 (4.14–4.89)* | 2.76 (2.30–3.35)* |
Odds ratio below 1 indicates in favor of VKA and above 1 in favor of rivaroxaban, apixaban or dabigatran. *Indicates significance.